Welltower Experiences 43.98% Surge in Trading Volume, Marking Its 208th Most Active Day as Shares Outperform S&P 500 Even With 1.2% Monthly Decline

Market Overview

On March 12, 2026, Welltower (WELL) saw trading volumes reach $630 million, marking a substantial 43.98% increase from the previous day. The stock ended the session up by 0.42%, indicating a slight positive movement amid heightened trading activity. Despite this daily uptick, Welltower experienced a 1.2% drop over the past month, although it still outperformed the S&P 500 during that period. The surge in volume placed Welltower at 208th among all stocks traded that day, reflecting both short-term investor interest and broader market influences.

Performance Highlights

Welltower’s recent results reveal a blend of robust financial fundamentals and cautious market sentiment. In the fourth quarter of 2025, the company reported normalized funds from operations (FFO) of $1.45 per share, exceeding the Zacks Consensus Estimate of $1.44 and representing a 28.3% increase year-over-year. Quarterly revenue climbed to $3.18 billion, up 41.3% from the previous year and well above the consensus estimate of $2.71 billion. This growth was largely fueled by the Seniors Housing Operating (SHO) portfolio, which saw same-store net operating income (SSNOI) rise 9.6% year-over-year, supported by a 400 basis-point improvement in average occupancy and a 4.7% increase in revenue per occupied room (RevPOR). The SHO segment was instrumental in driving the company’s overall portfolio SSNOI growth of 15%.

Despite these strong numbers, the stock’s 1.2% monthly decrease points to ongoing investor concerns. One major factor was a 37.2% year-over-year jump in property operating expenses, reaching $1.93 billion for the quarter. Welltower’s liquidity remains solid, with $10.2 billion in available resources—including $5.2 billion in cash and a $5 billion credit line—but rising costs could impact future profitability. The company’s guidance for 2026 projects normalized FFO per share between $6.09 and $6.25, with blended SSNOI growth expected to range from 11.25% to 15.75%. Notably, the SHO segment is forecasted to grow 15–21%, while other segments like Outpatient Medical and Long-Term/Post-Acute Care are anticipated to see more modest increases of 2.0–3.0%.

Analyst Perspectives and Industry Comparison

Analysts have shown cautious optimism toward Welltower. Over the past month, upward revisions in estimates reflect confidence in the company’s strategic moves, including $13.9 billion in pro-rata gross investments during Q4 2025 and plans for an additional $370 million in development projects for 2026. However, Welltower’s VGM (Value, Growth, Momentum) scores—C for Growth and Momentum, and F for Value—indicate that while growth prospects are promising, the stock may not appeal to value-oriented investors. The overall VGM Score of D suggests a neutral outlook for those without a specific investment focus.

Comparing Welltower to its peer Healthpeak (DOC) highlights broader industry trends. Healthpeak posted a 0.7% monthly gain, contrasting with Welltower’s decline, yet both companies hold a Zacks Rank #3 (Hold) and similar VGM scores. This points to sector-wide factors affecting performance, as the REIT and Equity Trust - Other industry continues to consolidate. Analysts have maintained their consensus estimates for Welltower, keeping a “Hold” rating, which suggests expectations for returns in line with the broader market.

Outlook

Welltower’s recent trading and earnings results highlight its status as a high-growth, capital-intensive REIT. While strong liquidity and impressive SSNOI growth in the SHO portfolio provide a solid base, rising operating costs and mixed VGM scores underscore the importance of operational efficiency. As the company heads into 2026, its ability to execute on development projects and control expenses will be key in determining whether the recent 1.2% decline is merely a short-term setback or signals a longer-term trend.